NCT01445535 2021-11-03Phase 1 Trial of Siplizumab and Dose-Adjusted EPOCH-Rituximab in T- and NK-Cell LymphomasNational Institutes of Health Clinical Center (CC)Phase 1 Completed15 enrolled 18 charts
NCT00806728 2008-12-11Study of MEDI-507 in With Steroid-Resistant Acute Graft-Versus-Host DiseaseMedImmune LLCPhase 1 Completed17 enrolled